present
studi
attempt
identifi
target
antigen
immunotherapi
cholangiocarcinoma
forkhead
box
select
candid
antigen
base
data
previou
cdna
microarray
analysi
clinic
sampl
cholangiocarcinoma
level
mrna
time
higher
cancer
cell
comparison
adjac
normal
epitheli
cell
sampl
cholangiocarcinoma
tissu
immunohistochem
analysi
also
detect
protein
cancer
cell
normal
cell
twentythre
human
peptid
predict
bind
analyz
determin
abil
induc
cell
transgen
mice
ylvpiqfpv
slvlqpsvkv
glmdlsttpl
peptid
prime
cytotox
lymphocyt
ctl
transgen
mice
human
ctl
line
reactiv
peptid
could
also
establish
healthi
donor
cancer
patient
natur
process
epitop
protein
confirm
specif
kill
peptideinduc
ctl
express
variou
type
cancer
also
function
involv
oncogen
transform
surviv
cancer
cell
therefor
may
suitabl
target
immunotherapi
variou
cancer
includ
cholangiocarcinoma
cholangiocarcinoma
devast
malign
difficult
diagnos
treat
unfortun
patient
consid
suitabl
surgeri
chemotherapi
radiotherapi
yield
substanti
improv
surviv
rate
overal
surviv
rate
poor
less
patient
surviv
upto
year
signific
chang
rate
past
year
recent
studi
identifi
therapeut
molecular
target
cholangiocarcinoma
preclin
studi
thu
support
therapeut
potenti
select
target
strategi
cholangiocarcinoma
result
encourag
although
obtain
vitro
studi
tumor
cell
xenograft
model
therefor
novel
therapeut
strategi
cholangiocarcinoma
urgent
need
cancer
immunotherapi
effect
induct
cytotox
lymphocyt
ctl
tumorassoci
antigen
taa
shown
promis
result
util
ctl
elicit
taa
ideal
therapeut
approach
specif
attack
tumor
cell
express
antigen
reveal
littl
advers
effect
normal
cell
develop
cdna
microarray
technolog
coupl
genom
inform
provid
comprehens
profil
gene
express
malign
cell
compar
normal
cell
taa
express
excess
preferenti
tumor
cell
present
studi
attempt
identifi
target
antigen
immunotherapi
cholangiocarcinoma
forkhead
box
select
candid
antigen
base
data
previou
cdna
microarray
analysi
clinic
sampl
cholangiocarcinoma
level
mrna
time
higher
cancer
cell
comparison
adjac
normal
epitheli
cell
sampl
cholangiocarcinoma
tissu
immunohistochem
analysi
also
detect
protein
cancer
cell
normal
cell
twentythre
human
peptid
predict
bind
analyz
determin
abil
induc
cell
transgen
mice
ylvpiqfpv
slvlqpsvkv
glmdlsttpl
peptid
prime
cytotox
lymphocyt
ctl
transgen
mice
human
ctl
line
reactiv
peptid
could
also
establish
healthi
donor
cancer
patient
natur
process
epitop
protein
confirm
specif
kill
peptideinduc
ctl
express
variou
type
cancer
also
function
involv
oncogen
transform
surviv
cancer
cell
therefor
may
suitabl
target
immunotherapi
variou
cancer
includ
cholangiocarcinoma
cholangiocarcinoma
devast
malign
difficult
diagnos
treat
unfortun
patient
consid
suitabl
surgeri
chemotherapi
radiotherapi
yield
substanti
improv
surviv
rate
overal
surviv
rate
poor
less
patient
surviv
upto
year
signific
chang
rate
past
year
recent
studi
identifi
therapeut
molecular
target
cholangiocarcinoma
preclin
studi
thu
support
therapeut
potenti
select
target
strategi
cholangiocarcinoma
result
encourag
although
obtain
vitro
studi
tumor
cell
xenograft
model
therefor
novel
therapeut
strategi
cholangiocarcinoma
urgent
need
cancer
immunotherapi
effect
induct
cytotox
lymphocyt
ctl
tumorassoci
antigen
taa
shown
promis
result
util
ctl
elicit
taa
ideal
therapeut
approach
specif
attack
tumor
cell
express
antigen
reveal
littl
advers
effect
normal
cell
develop
cdna
microarray
technolog
coupl
genom
inform
provid
comprehens
profil
gene
express
malign
cell
compar
normal
cell
taa
express
excess
preferenti
tumor
cell
normal
tissu
gene
express
profil
cdna
microarray
technolog
effect
approach
identif
new
taa
previou
studi
identifi
sever
molecular
target
use
diagnosi
immunotherapi
analyz
genomewid
gene
express
profil
variou
cancer
tissu
cdna
microarray
present
studi
identifi
candid
taa
forkhead
box
base
result
previou
cdna
microarray
analysi
tissu
patient
intrahepat
cholangiocarcinoma
recent
elev
express
report
varieti
human
cancer
includ
lung
cancer
common
caus
cancerrel
death
western
countri
among
normal
adult
human
organ
express
testi
thymu
small
intestin
colon
identif
immunodomin
epitop
taa
highlight
util
epitop
promis
therapeut
tool
cancer
immunotherapi
howev
identif
ctl
epitop
remain
difficult
mani
taaderiv
peptid
must
screen
immunogen
use
larg
number
peripher
blood
mononuclear
cell
pbmc
isol
patient
cancer
hla
transgen
mice
tgm
provid
versatil
anim
model
preclin
evalu
peptidebas
immunotherapi
previou
investig
use
tgm
identif
antigen
epitop
present
studi
identifi
epitop
use
tgm
ctl
line
reactiv
epitop
also
establish
cancer
patient
healthi
donor
data
present
herein
suggest
may
therefor
suitabl
target
immunotherapi
variou
cancer
includ
cholangiocarcinoma
intrahepat
cholangiocarcinoma
tissu
specimen
obtain
patient
underw
hepatectomi
kyoto
univers
hospit
written
inform
consent
tumor
histolog
diagnos
cholangiocarcinoma
pathologist
profil
gene
express
cdna
microarray
analysi
carri
describ
previous
mice
peptid
cell
line
transgen
mice
describ
previous
kindli
provid
dr
fa
lemonni
depart
sidaretroviru
unit
immunit
cellulair
antiviral
institut
pasteur
franc
peptid
puriti
purchas
anygen
gwangju
south
korea
three
human
cholangiocarcinoma
tfk
mec
two
human
hepatocellular
carcinoma
human
lung
cancer
cell
line
includ
adenocarcinoma
two
bronchioloalveolar
carcinoma
squamou
cell
carcinoma
rerflcai
adenosquam
carcinoma
largecel
carcinoma
smallcel
lung
cancer
use
human
saec
cell
use
control
transport
associ
antigen
process
tap
defici
hlaa
cell
line
colon
cancer
cell
line
obtain
riken
bioresourc
center
tsukuba
japan
cell
maintain
vitro
rpmi
medium
dmem
supplement
heat
inactiv
fetal
calf
serum
except
cell
cultur
medium
supplement
heat
inactiv
fetal
calf
serum
saec
cell
grown
optim
medium
sagm
purchas
cambrex
bio
scienc
walkersvil
md
clinic
research
use
pbmc
donor
approv
institut
review
board
kumamoto
univers
blood
sampl
obtain
healthi
donor
patient
either
cholangiocarcinoma
lung
cancer
provid
written
inform
consent
express
examin
flowcytometri
monoclon
antibodi
one
lambda
canoga
park
ca
select
donor
cancer
tissu
excis
patient
surgeri
obtain
written
inform
consent
total
rna
extract
cell
line
tissu
use
rneasi
kit
qiagen
dusseldorf
germani
accord
manufactur
instruct
total
rna
human
normal
tissu
purchas
clontech
palo
alto
ca
rtpcr
done
describ
previous
primer
sequenc
caccccagtgccaaccgc
detect
three
splice
variant
detect
variant
gapdh
actb
northern
blot
analysi
done
describ
previous
gel
lg
total
rna
human
normal
tissu
clontech
per
lane
blot
onto
nylon
membran
membran
hybrid
plabel
cdna
probe
blot
autoradiograph
intensifi
screen
c
hr
immunohistochem
analysi
done
describ
previous
section
paraffinembed
cholangiocarcinoma
lung
cancer
specimen
stain
mous
monoclon
antihuman
antibodi
clone
tumor
immunolog
tumorassoci
antigen
abnova
taipei
taiwan
standard
procedur
stain
signal
visual
use
dakocytom
envis
systemhrp
dakocytom
carpinteria
ca
cdna
encod
tag
influenza
viru
hemagglutinin
ha
clone
pentr
vector
invitrogen
carlsbad
ca
transfer
selfinactiv
lentiviru
express
vector
csiiefrfa
lr
recombin
reaction
invitrogen
lentivirousmedi
gene
transfer
perform
describ
previous
express
transgenederiv
protein
confirm
western
blot
analysi
use
horseradish
peroxidas
hrp
conjug
rat
monoclon
antiha
antibodi
clone
roch
mannheim
germani
bactin
also
detect
use
mous
monoclon
antibactin
antibodi
clone
sigma
st
loui
mo
hrpconjug
rabbit
antimous
igg
amersham
bioscienc
piscataway
nj
antibodi
signal
develop
visual
use
chemiluminesc
system
ecl
amersham
bioscienc
identif
ctl
epitop
use
transgen
mice
immun
mice
peptideload
bone
marrowderiv
dc
bmdc
done
previous
describ
spleen
cell
isol
immun
mice
frequenc
cell
produc
ifnc
among
cell
upon
stimul
syngen
well
bmdc
puls
without
peptid
assay
enzymelink
immunospot
elispot
assay
previous
descib
hlapeptidebind
assay
hlaa
tapdefici
cell
preincub
overnight
c
cultur
presenc
lm
peptid
lgml
b
microglobulin
sigma
st
loui
mo
serumfre
medium
c
hr
subsequ
c
hr
level
express
cell
surfac
analyz
flow
cytometri
use
monoclon
antibodi
human
cytomegalovirusderiv
peptid
qydpvaalf
neg
control
peptid
nlneslidl
sar
coronavirusderiv
ctl
epitop
peptid
high
bind
affin
work
prepar
posit
control
also
use
fluoresc
index
fi
calcul
mean
fluoresc
intens
mfi
express
cell
determin
flow
cytometri
use
formula
fi
mfi
cell
peptid
mfi
cell
cmvpeptid
pbmc
isol
heparin
blood
japanes
cancer
patient
healthi
donor
ficollconray
densiti
gradient
centrifug
peripher
monocytederiv
dendrit
cell
dc
gener
previous
describ
cell
isol
use
microbead
miltenyl
biotec
bergisch
gladbach
germani
pbmc
donor
thereaft
peptid
yokomin
et
al
reactiv
ctl
gener
describ
six
day
last
stimul
antigenspecif
respons
ctl
analyz
ifnc
elispot
assay
describ
also
cr
releas
assay
describ
previous
briefli
cr
label
target
cell
suspend
assay
medium
seed
well
plate
variou
number
effector
cell
suspend
assay
medium
ad
well
incub
hr
supernat
collect
well
measur
cr
radioact
statist
signific
differenti
find
among
experiment
group
determin
student
ttest
avalu
p
consid
statist
signific
laser
microdissectionbas
cdna
microarray
analysi
case
intrahepat
cholangiocarcinoma
report
previous
data
use
search
gene
show
high
rel
express
ratio
cancer
cell
normal
epitheli
cell
intrahepat
bile
duct
process
identifi
gene
greater
increas
express
cancer
cell
tissu
sampl
fig
among
upregul
gene
express
exhibit
greatest
increas
express
cancer
cell
comparison
normal
cell
fig
therefor
evalu
candid
antigen
immunotherapi
express
analyz
kind
normal
tissu
includ
fetal
kidney
liver
also
nonsmal
cell
lung
cancer
esophag
cancer
use
cdna
microarray
fig
express
testi
bone
marrow
small
intestin
thymu
fetal
liver
among
normal
tissu
howev
level
express
normal
tissu
far
lower
nonsmal
cell
lung
carcinoma
esophag
cancer
tissu
fig
previous
report
data
cdna
microarray
analysi
variou
kind
cancer
tissu
use
analyz
express
differ
type
cancer
tissu
support
inform
tabl
show
express
elev
variou
cancer
tissu
particularli
enhanc
express
recogn
bladder
cancer
lung
cancer
small
cell
carcinoma
nonsmal
cell
carcinoma
pancreat
cancer
investig
conduct
cholangiocarcinoma
also
lung
cancer
lung
cancer
common
caus
cancer
death
western
countri
express
gene
cholangiocarcinoma
hepatocellular
carcinoma
lung
cancer
cell
line
adenocarcinoma
bronchioloalveolar
carcinoma
squamou
cell
carcinoma
adenosquam
carcinoma
larg
cell
carcinoma
small
cell
carcinoma
lung
cancer
tissu
analyz
rtpcr
gene
contain
exon
altern
express
give
rise
differenti
express
mrna
isoform
cholangiocarcinoma
cell
line
tfk
mec
hepatocellular
carcinoma
cell
line
strongli
express
mrna
fig
express
lung
cancer
cell
line
examin
support
inform
fig
addit
tissu
sampl
lung
adenocarcinoma
squamou
cell
carcinoma
small
cell
carcinoma
also
express
mrna
wherea
normal
lung
epithelium
support
inform
fig
strongli
express
cancer
cell
line
examin
except
colon
cancer
cell
line
express
trace
amount
mrna
data
shown
among
normal
tissu
specimen
mrna
express
testi
fetal
liver
thymu
stomach
small
intestin
colon
fig
northern
blot
analysi
reveal
rel
strong
express
mrna
testi
weak
express
fetal
liver
thymu
gastrointestin
tract
fig
rtpcr
northern
blot
analys
consist
result
cdna
microarray
analysi
fig
tissu
sampl
cholangiocarcinoma
lung
cancer
analyz
immunohistochem
determin
express
protein
cancer
cell
fig
yokomin
et
al
increas
express
protein
observ
cancer
tissu
adjac
normal
tissu
identif
epitop
use
tgm
human
peptid
carri
bind
motif
hlaa
search
use
bima
softwar
packag
bioinformat
molecular
analysi
section
center
inform
technolog
nih
bethesda
md
http
wwwbimascitnihgov
syfpeithi
biomed
informat
http
wwwsyfpeithid
select
peptid
predict
bind
amino
acid
sequenc
conserv
among
human
isoform
score
select
peptid
calcul
base
bima
syfpeithi
algorithm
predict
affin
shown
tabl
investig
conduct
identifi
epitop
select
peptid
use
tgm
peptid
load
onto
bmdc
tgm
inject
intraperiton
twice
mice
interv
spleen
cell
isol
mice
day
second
inject
cultur
bmdc
puls
peptid
subsequ
cultur
cell
subject
elispot
assay
analyz
product
ifnc
upon
stimul
peptid
seri
repeat
experi
reveal
reproduc
respons
design
respect
tabl
fig
hand
peptidereact
ctl
line
respond
peptid
puls
onto
nontransgen
micederiv
bmdc
thu
verifi
respons
peptid
restrict
amino
acid
sequenc
conserv
human
mous
wherea
conserv
human
glmdlsttpl
vs
mous
glm
elnttpl
determin
whether
immun
mice
peptid
caus
autoimmun
histolog
analysi
done
variou
organ
isol
tgm
immun
peptid
observ
patholog
chang
lymphocyt
infiltr
tissu
destruct
repair
brain
heart
lung
liver
small
intestin
kidney
testi
immun
tgm
data
shown
result
suggest
ctl
respons
elicit
immun
peptid
may
caus
damag
normal
tissu
know
whether
identifi
peptid
actual
bind
analyz
bind
peptid
use
tapdefici
cell
shown
figur
stabil
cell
surfac
addit
peptid
observ
thu
confirm
actual
bind
peptid
thereaft
investig
human
ctl
respons
tri
establish
ctl
line
pbmc
healthi
individu
stimul
peptid
cell
sort
pbmc
cocultur
autolog
monocytederiv
dc
puls
peptid
describ
materi
method
ctl
line
gener
posit
healthi
donor
produc
ifnc
specif
respons
restimul
cell
puls
peptid
fig
investig
examin
whether
identifi
peptid
produc
protein
intracellular
natur
process
kill
activ
ctl
induc
peptid
cancer
patient
analyz
cr
releas
assay
rtpcr
analys
reveal
posit
cell
line
examin
express
fig
support
inform
fig
data
shown
except
cell
thu
introduc
cell
express
vector
use
lentiviru
use
target
cell
cell
infect
lentivirus
without
also
use
neg
control
target
cell
express
transgenederiv
protein
transfect
confirm
shown
figur
peptideinduc
ctl
line
exhibit
significantli
higher
cytotox
cell
caco
yokomin
et
al
result
clearli
indic
peptid
natur
process
protein
present
context
recogn
peptideinduc
ctl
identif
adequ
target
antigen
induc
potent
specif
antitumor
immun
respons
import
develop
cancer
immunotherapi
although
mani
taa
variou
cancer
identifi
antigen
specif
express
cholangiocarcinoma
report
previou
cdna
microarray
analysi
identifi
multipl
gene
transcript
upor
downregul
cholangiocarcinoma
current
studi
search
taa
use
cdna
microarray
data
identifi
candid
target
antigen
overexpress
number
aggress
human
carcinoma
enhanc
express
also
observ
variou
cancer
tissu
cdna
microarray
analysi
support
inform
tabl
express
significantli
associ
poor
overal
surviv
nonsmal
cell
lung
cancer
glioblastoma
patient
therefor
may
potenti
serv
good
target
cancer
immunotherapi
variou
type
cancer
evalu
target
cancer
immunotherapi
present
studi
examin
immunogen
human
immun
system
peptid
predict
bind
analyz
capac
induc
ctl
stimul
pbmc
obtain
healthi
donor
ylvpiqfpv
slvlqpsvkv
glmdlsttpl
peptid
result
gener
peptidereact
ctl
line
furthermor
ctl
reactiv
peptid
gener
cancer
patient
exhibit
specif
cytotox
hlaa
cell
introduc
express
vector
mockintroduc
cell
thu
verifi
natur
process
peptid
protein
cancer
cell
result
suggest
promis
target
variou
type
cancer
peptid
deriv
effect
tool
clinic
applic
peptidebas
immunotherapi
hlaa
cancer
patient
human
gene
structur
two
exon
va
viia
altern
splice
differenti
splice
exon
va
viia
human
yield
isoform
contain
altern
exon
contain
none
altern
exon
retain
exon
va
exhibit
transactiv
activ
absenc
viia
inhibitori
sequenc
presenc
viia
render
transcript
inact
present
studi
found
express
variou
cancer
cell
sampl
differenti
pattern
express
normal
testi
thymu
isoform
abund
cultur
cell
includ
normal
gastrointestin
tract
result
consist
find
studi
transcript
factor
play
import
role
regul
express
gene
involv
cell
growth
prolifer
differenti
longev
transform
express
profil
identifi
cluster
gene
includ
mani
gene
cyclin
b
cenpf
etc
loss
express
cancer
cell
line
result
mitot
spindl
defect
delay
cell
mitosi
induc
mitot
catastroph
find
suggest
express
essenti
cancer
cell
growth
surviv
inde
evid
express
mrna
detect
cell
line
examin
rtpcr
present
studi
molecul
express
cancer
cell
play
essenti
role
surviv
cancer
cell
escap
immun
cell
attack
direct
molecul
lose
express
molecul
regard
thu
consid
suitabl
target
anticanc
immunotherapi
hla
tgm
use
identif
hlarestrict
antigen
epitop
also
evalu
autoimmun
caus
immun
peptid
conserv
human
mous
amino
acid
sequenc
peptid
conserv
human
mous
present
studi
vaccin
peptid
induc
autoimmun
tgm
result
suggest
use
peptid
hlaa
human
would
safe
although
low
level
express
detect
normal
organ
fig
number
clinic
trial
evalu
peptid
deriv
taa
howev
tumor
regress
far
observ
expect
possibl
reason
lack
clinic
efficaci
could
entri
advanc
cancer
patient
immunotherapi
trial
loss
downregul
hla
class
molecul
costimulatori
molecul
protein
associ
antigen
present
tap
lowmolecularweight
protein
lmp
b
microglobulin
tumor
cell
consequ
signific
portion
tumor
cell
could
escap
ctl
specif
taaderiv
peptid
present
hla
class
molecul
even
ctl
could
success
induc
taa
peptid
vaccin
capabl
target
tumor
cell
present
studi
investig
express
tumor
escapeassoci
gene
specimen
intrahepat
cholangiocarcinoma
tissu
use
cdna
microarray
analysi
downregul
gene
associ
immun
escap
observ
data
shown
result
suggest
ctlmediat
immunotherapi
cholangiocarcinoma
could
effect
recent
two
inhibitor
transcript
activ
identifi
target
inhibitor
effect
anticanc
therapi
one
peptid
contain
amino
acid
sequenc
arf
interact
ctermin
transactiv
domain
inhibit
transcript
activ
peptid
caus
select
apoptosi
hepatocellular
carcinoma
overexpress
reduc
prolifer
angiogenesi
hepatocellular
carcinoma
region
adjac
normal
liver
tissu
mice
antibiot
thiazol
compound
siomycin
antibiot
inhibit
anchorageindepend
growth
select
induc
apoptosi
cell
could
potenti
anticanc
drug
although
result
base
experi
cell
line
transgen
mice
clinic
trial
epitopepeptid
vaccin
deriv
taa
identifi
genomewid
cdna
microarray
analys
differ
cancer
current
underway
epitop
identifi
present
studi
may
well
clinic
test
near
futur
